ArticleCancer discovery2019
Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the
Abstract read
In one paragraph
Article in Cancer discovery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 164 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
164citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
164 citing papers in PubMed, 2 syntheses or guidelines pooled it, 154 citations in OpenAlex.
- Novel Therapeutic Strategies for Metastatic Prostate Cancer Care.European urology · 2025Pooled it
- tRNA-derived fragments: mechanism of gene regulation and clinical application in lung cancer.Cellular oncology (Dordrecht, Netherlands) · 2024Pooled it
- Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.Cancer discovery · 2020Trial
- Exceptional treatment responses and molecular markers among 103 colorectal cancer cell lines.Molecular biomedicine · 2026Article
- AURORA A interacts with DICER and SETD2 to promote S-phase progression.EMBO reports · 2026Article
- miR-640 Enhances Abemaciclib Sensitivity by Suppressing CDK Inhibitor Resistance-Associated Genes in Breast Cancer Cells.Journal of cellular and molecular medicine · 2026Article
- Dual Inhibition of TRIP13 and Aurora A Induces Mitotic DNA Damage and Concurrent Pyroptotic-Apoptotic Cell Death in Rb-Deficient Cancer Cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- KMT2D loss drives adeno-to-squamous transition and sensitizes TKI-resistant lung cancer to AURKA inhibition.Cell death and differentiation · 2026Article
- Aurora-A drives sorafenib resistance by scaffolding stress granule assembly via phase separation.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Emerging Strategies to Inhibit the G1/S Transition for Cancer Therapy.Cancer research · 2026Review
- Homologous recombination deficiency and hemizygosity drive resistance in breast cancer.Nature · 2026Article
- Tyrosine phosphoproteome profiling identifies cell-intrinsic signals limiting the efficacy of tyrosine kinase inhibitor therapies.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Survivin and Aurora Kinase A control cell fate decisions during mitosis.Molecular oncology · 2026Article
- RB1-I680T mutation potentiates tumor growth and chemotherapy sensitivity in non-small cell lung cancer via derepressing E2F1 transcription.Cell communication and signaling : CCS · 2026Article
- Tumor suppressor genes and KRAS G12C inhibitor resistance in non-small cell lung cancer.iScience · 2026Review
- Mechanistic insights and molecular therapy for neuroendocrine prostate cancer.Frontiers in oncology · 2026Review
- Review
- Discovery of the first-in-class Aurora B kinase selective degrader.European journal of medicinal chemistry · 2025Article
- Discovery of a Potent and Highly Selective Inhibitor of Aurora A Kinase.ACS medicinal chemistry letters · 2025Article
104 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
41 authors at 1 institution in 1 country.
Xueqian Gong *Eli Lilly and Company, Indianapolis, Indiana.
Jian Du *Eli Lilly and Company, Indianapolis, Indiana.
Stephen H Parsons *Eli Lilly and Company, Indianapolis, Indiana.
Farhana F MerzougEli Lilly and Company, Indianapolis, Indiana.
Yue WebsterEli Lilly and Company, Indianapolis, Indiana.
Philip W IversenEli Lilly and Company, Indianapolis, Indiana.
Li-Chun ChioEli Lilly and Company, Indianapolis, Indiana.
Robert D Van HornEli Lilly and Company, Indianapolis, Indiana.
Xi LinEli Lilly and Company, Indianapolis, Indiana.
Wayne BlosserEli Lilly and Company, Indianapolis, Indiana.
Bomie HanEli Lilly and Company, Indianapolis, Indiana.
Shaoling JinEli Lilly and Company, Indianapolis, Indiana.
Sufang YaoEli Lilly and Company, Indianapolis, Indiana.
Huimin BianEli Lilly and Company, Indianapolis, Indiana.
Chris FicklinEli Lilly and Company, Indianapolis, Indiana.
Li FanEli Lilly and Company, Indianapolis, Indiana.
Avnish KapoorEli Lilly and Company, Indianapolis, Indiana.
Stephen AntonysamyEli Lilly and Company, Discovery Chemistry Research and Technologies, Lilly Biotechnology Center, San Diego, California.
Ann M Mc NultyEli Lilly and Company, Indianapolis, Indiana.
Karen FroningEli Lilly and Company, Discovery Chemistry Research and Technologies, Lilly Biotechnology Center, San Diego, California.
Danalyn ManglicmotEli Lilly and Company, Discovery Chemistry Research and Technologies, Lilly Biotechnology Center, San Diego, California.
Anna PustilnikEli Lilly and Company, Discovery Chemistry Research and Technologies, Lilly Biotechnology Center, San Diego, California.
Kenneth WeichertEli Lilly and Company, Discovery Chemistry Research and Technologies, Lilly Biotechnology Center, San Diego, California.
Stephen R WassermanEli Lilly and Company, Advanced Photon Source, Argonne National Laboratory, Argonne, Illinois.
Michele DowlessEli Lilly and Company, Indianapolis, Indiana.
Carlos MarugánEli Lilly and Company, Lilly Research Laboratories, Avenida de la Industria, Alcobendas, Spain.
Carmen BaqueroEli Lilly and Company, Lilly Research Laboratories, Avenida de la Industria, Alcobendas, Spain.
María José LallenaEli Lilly and Company, Lilly Research Laboratories, Avenida de la Industria, Alcobendas, Spain.
Scott W EastmanEli Lilly and Company, Alexandria Center for Life Sciences, New York, New York.
Yu-Hua HuiEli Lilly and Company, Indianapolis, Indiana.
Matthew Z DieterEli Lilly and Company, Indianapolis, Indiana.
Thompson DomanEli Lilly and Company, Indianapolis, Indiana.
Shaoyou ChuEli Lilly and Company, Indianapolis, Indiana.
Hui-Rong QianEli Lilly and Company, Indianapolis, Indiana.
Xiang S YeEli Lilly and Company, Indianapolis, Indiana.
David A BardaEli Lilly and Company, Indianapolis, Indiana.
Gregory D PlowmanEli Lilly and Company, Indianapolis, Indiana.
Christoph ReinhardEli Lilly and Company, Indianapolis, Indiana.
Robert M CampbellEli Lilly and Company, Indianapolis, Indiana.
James R HenryEli Lilly and Company, Indianapolis, Indiana.
Sean G BuchananEli Lilly and Company, Indianapolis, Indiana. buchananse@lilly.com.ORCID 0000-0002-5215-4672
Eli Lilly (United States) · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
Loss-of-function mutations in the retinoblastoma gene
Indexed as
AnimalsAntineoplastic AgentsApoptosisAurora Kinase ABreast NeoplasmsCell Cycle CheckpointsCell ProliferationEnzyme InhibitorsFemaleHumansLung NeoplasmsMiceMice, NudeM Phase Cell Cycle CheckpointsRetinoblastoma Binding ProteinsSignal TransductionAntineoplastic AgentsAURKA protein, humanAurora Kinase AEnzyme InhibitorsRB1 protein, humanRetinoblastoma Binding ProteinsUbiquitin-Protein Ligases
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.